AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory: Phenylbutazone exerts its therapeutic effects by inhibiting the production of prostaglandins, which are substances involved in inflammation and pain. It helps reduce pain, swelling, and inflammation associated with various musculoskeletal disorders.
Analgesic: Phenylbutazone has analgesic properties, providing relief from pain associated with inflammatory conditions such as arthritis and gout.
Antipyretic: Like other NSAIDs, phenylbutazone can help reduce fever by inhibiting prostaglandin synthesis in the brain's hypothalamus, which regulates body temperature.
Musculoskeletal Disorders: Phenylbutazone has been used to treat conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and gout. It helps alleviate pain, stiffness, and swelling associated with these disorders.
Equine Use: Phenylbutazone has been widely used in horses for the treatment of musculoskeletal injuries and lameness. It is often administered orally or intravenously in equine medicine.
Adverse Gastrointestinal Effects: Like other NSAIDs, phenylbutazone can cause gastrointestinal adverse effects, including stomach ulcers, gastritis, gastrointestinal bleeding, and perforation. These effects can be severe and may lead to complications such as gastrointestinal hemorrhage or perforation.
Cardiovascular Effects: Phenylbutazone may increase the risk of cardiovascular events, including heart attack and stroke, particularly with long-term use or in individuals with pre-existing cardiovascular disease.
Renal Effects: Phenylbutazone can impair kidney function and may cause kidney damage, particularly in individuals with pre-existing kidney disease or those at risk of renal impairment.
Hematological Effects: Phenylbutazone can suppress bone marrow function, leading to decreased production of blood cells (anemia, leukopenia, and thrombocytopenia).
Hypersensitivity Reactions: Some individuals may experience allergic reactions to phenylbutazone, ranging from mild skin rash to severe anaphylaxis.
Hepatic Effects: Phenylbutazone has been associated with liver toxicity and may cause liver damage, particularly with long-term use or in individuals with pre-existing liver disease.
Skin Reactions: Phenylbutazone can cause adverse skin reactions, including rash, itching, photosensitivity, and Stevens-Johnson syndrome (a severe skin reaction).
Central Nervous System Effects: Phenylbutazone may cause central nervous system side effects such as headache, dizziness, drowsiness, and confusion.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.1 | -0.1 | |
| ADHD | 0.5 | 0.3 | 0.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.2 | -1 |
| Allergic Rhinitis (Hay Fever) | 0.7 | 0.2 | 2.5 |
| Allergies | 1.1 | 0.7 | 0.57 |
| Allergy to milk products | 0.6 | 0.3 | 1 |
| Alopecia (Hair Loss) | 0.8 | 0.8 | |
| Alzheimer's disease | 0.3 | 0.8 | -1.67 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | 0 |
| Ankylosing spondylitis | 1.6 | 0.2 | 7 |
| Anorexia Nervosa | 0.2 | 0.6 | -2 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 1.1 | 0.2 | 4.5 |
| Atherosclerosis | 0.4 | 0.4 | 0 |
| Atrial fibrillation | 0.7 | 0.8 | -0.14 |
| Autism | 3.8 | 1.5 | 1.53 |
| Barrett esophagus cancer | 0.2 | -0.2 | |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.4 | 0.4 | 0 |
| Brain Trauma | 0.4 | 0.2 | 1 |
| Carcinoma | 1.3 | 0.7 | 0.86 |
| Celiac Disease | 0.5 | 0.4 | 0.25 |
| Cerebral Palsy | 0.6 | 0.2 | 2 |
| Chronic Fatigue Syndrome | 2.8 | 1.3 | 1.15 |
| Chronic Kidney Disease | 0.8 | 0.4 | 1 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.1 | 10 |
| Chronic Urticaria (Hives) | 0.7 | 0.3 | 1.33 |
| Coagulation / Micro clot triggering bacteria | 0.6 | 0.3 | 1 |
| Colorectal Cancer | 1.4 | 0.4 | 2.5 |
| Constipation | 0.2 | 0.1 | 1 |
| Coronary artery disease | 0.3 | 0.3 | |
| COVID-19 | 3.3 | 3.2 | 0.03 |
| Crohn's Disease | 1.6 | 0.8 | 1 |
| cystic fibrosis | 0.2 | 0.3 | -0.5 |
| deep vein thrombosis | 0.2 | 0.3 | -0.5 |
| Depression | 4.7 | 2.5 | 0.88 |
| Dermatomyositis | 0.2 | 0.1 | 1 |
| Eczema | 0.1 | 1.4 | -13 |
| Endometriosis | 0.8 | 0.8 | |
| Epilepsy | 0.8 | 0.8 | 0 |
| Fibromyalgia | 0.9 | 0.8 | 0.13 |
| Functional constipation / chronic idiopathic constipation | 1 | 1.6 | -0.6 |
| gallstone disease (gsd) | 0.6 | 0.1 | 5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | -0.2 | |
| Generalized anxiety disorder | 0.2 | 0.5 | -1.5 |
| giant cell arteritis | 0.3 | -0.3 | |
| Glioblastoma | 0.2 | -0.2 | |
| Graves' disease | 0.7 | 0.4 | 0.75 |
| Halitosis | 0.2 | 0.2 | 0 |
| Hashimoto's thyroiditis | 0.3 | 0.2 | 0.5 |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 0.1 | 0.4 | -3 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.3 | 0.33 |
| hypertension (High Blood Pressure | 1 | 0.7 | 0.43 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 0.8 | -0.8 | |
| Inflammatory Bowel Disease | 2 | 2.1 | -0.05 |
| Insomnia | 0.4 | 0.2 | 1 |
| Intelligence | 0.3 | 0.3 | 0 |
| Intracranial aneurysms | 0.4 | 0.3 | 0.33 |
| Irritable Bowel Syndrome | 1.5 | 0.6 | 1.5 |
| Liver Cirrhosis | 1.1 | 0.8 | 0.38 |
| Long COVID | 2.8 | 1.5 | 0.87 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.7 | 0.7 | |
| ME/CFS with IBS | 1.3 | 0.2 | 5.5 |
| ME/CFS without IBS | 1.7 | 0.7 | 1.43 |
| Menopause | 0.2 | 0.2 | |
| Metabolic Syndrome | 3.2 | 1.2 | 1.67 |
| Mood Disorders | 5.7 | 2.9 | 0.97 |
| multiple chemical sensitivity [MCS] | 1 | 1 | |
| Multiple Sclerosis | 2.4 | 2.5 | -0.04 |
| Multiple system atrophy (MSA) | 0.2 | 0.1 | 1 |
| Neuropathy (all types) | 0.2 | 0.1 | 1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 0.4 | 2 |
| NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
| Obesity | 2.8 | 1.6 | 0.75 |
| obsessive-compulsive disorder | 0.8 | 0.5 | 0.6 |
| Osteoarthritis | 0.8 | 0.8 | |
| Osteoporosis | 0.9 | 0.2 | 3.5 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 1.3 | 0.4 | 2.25 |
| Polycystic ovary syndrome | 0.7 | 0.4 | 0.75 |
| Postural orthostatic tachycardia syndrome | 0.3 | 0.1 | 2 |
| Premenstrual dysphoric disorder | 0.4 | 0.2 | 1 |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Psoriasis | 1.3 | 1.2 | 0.08 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.3 | 0.9 | 1.56 |
| Rosacea | 0.1 | 0.4 | -3 |
| Schizophrenia | 2.1 | 0.4 | 4.25 |
| Sjögren syndrome | 0.8 | 0.5 | 0.6 |
| Sleep Apnea | 0.1 | 0.6 | -5 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.9 | 1.3 | -0.44 |
| Systemic Lupus Erythematosus | 1 | 0.1 | 9 |
| Tic Disorder | 0.7 | -0.7 | |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 0.3 | 0.7 | -1.33 |
| Type 2 Diabetes | 2.8 | 1.1 | 1.55 |
| Ulcerative colitis | 1 | 1.2 | -0.2 |
| Unhealthy Ageing | 1.5 | 0.2 | 6.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.